( ediators (cytokines) playing a role for...)Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy,Health

ediators (cytokines) playing a role for other immune cells. A Th1 type immune response is usually induced by viral or bacterial infection,
or also by potent vaccination / immunotherapy. A Th2 type immune response usually manifests an allergic reaction.

This foregoing press release may contain forward-looking statements that include words or phrases such as “seem”, “appear”, “will”,
“designed”, “aim”, “may”, “intend” or other similar expressions. These forward-looking statements are subject to a variety of significant
uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those
presented. There can be no assurance that any other therapeutic entities will enter clinical trials, that clinical trial results will be
predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will
receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed
successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes
no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute
an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology AG.
'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis